Lex­eo Ther­a­peu­tics pen­cils in $113M IPO for car­diac and Alzheimer's gene ther­a­py read­outs in 2024

Ex­ec­u­tives at gene ther­a­py start­up Lex­eo Ther­a­peu­tics will like­ly make the 25-minute trek from their head­quar­ters to Nas­daq’s trad­ing floor lat­er this week in the biotech’s bid for a $113 mil­lion ini­tial pub­lic of­fer­ing.

With just $35 mil­lion on hand at the end of Sep­tem­ber, the car­diac and Alzheimer’s biotech will look to the un­for­giv­ing pub­lic mar­kets as the rel­a­tive­ly non-ex­is­tent IPO win­dow clos­es ahead of the hol­i­days. On Mon­day, the com­pa­ny sub­mit­ted its Nas­daq de­but pitch for 9 mil­lion shares as “LX­EO,” at $13 to $15 apiece.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER